Based on the IMROZ and BENEFIT data, would you recommend quadruplet therapy for non transplant eligible newly diagnosed multiple myeloma?

Community PollStarted

For what proportion of your transplant-ineligible patients with multiple myeloma will you plan to prescribe a quadruplet?

15 physicians have voted

Join Mednetto vote and see how they answered.

1 Answer

Mednet MemberInvited Expert

Medical Oncology · University of Washington, Fred Hutchinson Cancer Research Center

Answered on

Excellent question - to add citations for those who missed ASCO 2024 (I did since I was on inpatient!) and would like to jump to the manuscripts:

IMROZ: Isa-VRd versus VRd (Facon et al., PMID 38832972)
BENEFIT/IFM 2020-05: Isa-VRd versus Isa-Rd (Leleu et al., PMID 38830994)

Both trials enrolled pati...

Join for free or sign in to see the full answer